newsfilter
← Latest News
GlobeNewswire·

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

  • Pliant Therapeutics, Inc. announced participation in the 2026 RBC Capital Markets Global Healthcare Conference.
  • CEO Bernard Coulie, M.D., Ph.D., & CFO Keith Cummings, M.D., will participate in a fireside chat on Tuesday, May 19, 2026, at 11:30 a.m. Eastern Time.
  • The live webcast & a 30-day replay archive will be accessible via the Investor Relations' Events & Presentation page on Pliant's website.
  • Pliant's lead program is PLN-101095, an oral, dual-selective small molecule inhibitor of α v ß 8 & α v ß 1 integrins for ICI-refractory advanced or metastatic solid tumors.
  • PLN-101095 is being investigated in the FORTIFY Phase 1b trial for NSCLC, tumors with high tumor mutational burden, or clear cell renal cell carcinoma.
  • Preclinical research focuses on tissue-specific delivery of drug payloads via integrin receptor-binding molecules, including siRNAs for skeletal muscle cells, adipocytes, & renal cells.